-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
-
Despite their advantages in preventing restenosis, drug-eluting stents (DES) have recently been found to be at risk for late stent thrombosis.
-
A longstanding controversy exists regarding the importance of a patent foramen ovale (PFO) as a cause for TIA or stroke.
-
The Food and Drug Administration (FDA) cautions about increased risks of adverse events with the combination of statins and niacin, yet achieving current lipid treatment targets often requires multiple drug therapy.
-
The role of statins in heart failure patients is poorly studied and controversial. Thus, Khush and colleagues analyzed the secondary endpoint in the Treating to New Targets (TNT) study of hospitalization for heart failure.
-
Gami and his colleagues from the Mayo Clinic describe in this paper relationships between obesity, obstructive sleep apnea, and atrial fibrillation (AF).
-
Two recent large studies have looked at the effects of various inhaler combinations on outcomes in patients with COPD.
-
-
Small dense low-density lipoprotein cholesterol (LDL-C) particles are believed to be more atherogenic than large ones.
-
This paper describes results from a multi-center registry located at the Minneapolis Heart Institute Foundation that collects data on device failure in pacemakers and implantable defibrillators.
